GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Capricor Therapeutics Inc (FRA:4LN2) » Definitions » Deferred Policy Acquisition Costs

Capricor Therapeutics (FRA:4LN2) Deferred Policy Acquisition Costs


View and export this data going back to 2010. Start your Free Trial

What is Capricor Therapeutics Deferred Policy Acquisition Costs?

Deferred Policy Acquisition Costs only applies to banks and insurance companies.


Capricor Therapeutics (FRA:4LN2) Business Description

Traded in Other Exchanges
Address
10865 Road to the Cure, Suite 150, San Diego, CA, USA, 92121
Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.